Abstract: The subject invention provides CAI compounds and formulations thereof, and methods for their use in the localized treatment of non-life threatening diseases. Formulations of CAI compounds of the subject invention include CAI free base and CAI prodrug microcrystallines, microparticles, emulsions, and the like. The subject invention further provides methods for treating non-life threatening diseases using the CAI compounds of the invention (i.e., novel delivery systems and combination therapies), that are effective and are associated with little or no adverse side effects.
Type:
Application
Filed:
September 22, 2016
Publication date:
January 12, 2017
Applicant:
RFE Pharma LLC
Inventors:
Gary Robinson, Gideon Shapiro, Alan J. Franklin, Simona Jurczyk
Abstract: The subject invention provides CAI compounds and formulations thereof, and methods for their use in the localized treatment of non-life threatening diseases. Formulations of CAI compounds of the subject invention include CAI free base and CAI prodrug microcrystallines, microparticles, emulsions, and the like. The subject invention further provides methods for treating non-life threatening diseases using the CAI compounds of the invention (i.e., novel delivery systems and combination therapies), that are effective and are associated with little or no adverse side effects.
Type:
Application
Filed:
February 6, 2014
Publication date:
June 5, 2014
Applicant:
RFE Pharma LLC
Inventors:
Gary Robinson, Gideon Shapiro, Alan J. Franklin, Simona Jurczyk
Abstract: The subject invention provides CAI compounds and formulations thereof, and methods for their use in the localized treatment of non-life threatening diseases. Formulations of CAI compounds of the subject invention include CAI free base and CAI prodrug microcrystallines, microparticles, emulsions, and the like. The subject invention further provides methods for treating non-life threatening diseases using the CAI compounds of the invention (i.e., novel delivery systems and combination therapies), that are effective and are associated with little or no adverse side effects.
Type:
Application
Filed:
November 19, 2013
Publication date:
March 20, 2014
Applicant:
RFE Pharma LLC
Inventors:
GARY ROBINSON, Gideon Shapiro, Alan J. Franklin, Simona Jurczyk
Abstract: The subject invention provides CAI compounds and formulations thereof, and methods for their use in the localized treatment of non-life threatening diseases. Formulations of CAI compounds of the subject invention include CAI free base and CAI prodrug microcrystallines, microparticles, emulsions, and the like. The subject invention further provides methods for treating non-life threatening diseases using the CAI compounds of the invention (i.e., novel delivery systems and combination therapies) that are effective and are associated with little or no adverse side effects.
Type:
Grant
Filed:
July 13, 2011
Date of Patent:
December 24, 2013
Assignee:
RFE Pharma LLC
Inventors:
Gary Robinson, Gideon Shapiro, Alan J. Franklin, Simona Jurczyk